Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Periodically rotated overlapping parallel lines with enhanced reconstruction acquisition to improve motion-induced artifacts in bladder cancer imaging: Initial findings.

Nguyen HT, Shah ZK, Mortazavi A, Pohar KS, Wei L, Zynger DL, Knopp MV.

Medicine (Baltimore). 2019 Oct;98(42):e17075. doi: 10.1097/MD.0000000000017075.

2.

Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients.

Williams SB, Kamat AM, Chamie K, Froehner M, Wirth MP, Wiklund PN, Black PC, Steinberg GD, Boorjian SA, Daneshmand S, Goebell PJ, Pohar KS, Shariat SF, Thalmann GN.

Eur Urol Oncol. 2018 Jun;1(2):91-100. doi: 10.1016/j.euo.2018.03.005. Epub 2018 Jun 6.

3.

NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.

Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA.

J Natl Compr Canc Netw. 2018 Sep;16(9):1041-1053. doi: 10.6004/jnccn.2018.0072.

PMID:
30181416
4.

Quantitative Assessment of Heterogeneity in Bladder Tumor MRI Diffusivity: Can Response be Predicted Prior to Neoadjuvant Chemotherapy?

Nguyen HT, Mortazavi A, Pohar KS, Zynger DL, Wei L, Shah ZK, Jia G, Knopp MV.

Bladder Cancer. 2017 Oct 27;3(4):237-244. doi: 10.3233/BLC-170110.

5.

Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA.

J Natl Compr Canc Netw. 2017 Oct;15(10):1240-1267. doi: 10.6004/jnccn.2017.0156.

PMID:
28982750
6.

A prospective comparison of UroVysion FISH and urine cytology in bladder cancer detection.

Lavery HJ, Zaharieva B, McFaddin A, Heerema N, Pohar KS.

BMC Cancer. 2017 Apr 7;17(1):247. doi: 10.1186/s12885-017-3227-3.

7.

Dosage-dependent copy number gains in E2f1 and E2f3 drive hepatocellular carcinoma.

Kent LN, Bae S, Tsai SY, Tang X, Srivastava A, Koivisto C, Martin CK, Ridolfi E, Miller GC, Zorko SM, Plevris E, Hadjiyannis Y, Perez M, Nolan E, Kladney R, Westendorp B, de Bruin A, Fernandez S, Rosol TJ, Pohar KS, Pipas JM, Leone G.

J Clin Invest. 2017 Mar 1;127(3):830-842. doi: 10.1172/JCI87583. Epub 2017 Jan 30.

8.

Does the gross prosector impact pT3 subclassification or lymph node counts in bladder cancer?

Tretter EM, Ebel JJ, Pohar KS, Zynger DL.

Hum Pathol. 2017 Mar;61:190-198. doi: 10.1016/j.humpath.2016.12.009. Epub 2016 Dec 16.

PMID:
27993579
9.

NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.

Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C.

J Natl Compr Canc Netw. 2016 Oct;14(10):1213-1224.

10.

Non-invasive quantification of tumour heterogeneity in water diffusivity to differentiate malignant from benign tissues of urinary bladder: a phase I study.

Nguyen HT, Shah ZK, Mortazavi A, Pohar KS, Wei L, Jia G, Zynger DL, Knopp MV.

Eur Radiol. 2017 May;27(5):2146-2152. doi: 10.1007/s00330-016-4549-2. Epub 2016 Aug 23.

11.

E2f8 mediates tumor suppression in postnatal liver development.

Kent LN, Rakijas JB, Pandit SK, Westendorp B, Chen HZ, Huntington JT, Tang X, Bae S, Srivastava A, Senapati S, Koivisto C, Martin CK, Cuitino MC, Perez M, Clouse JM, Chokshi V, Shinde N, Kladney R, Sun D, Perez-Castro A, Matondo RB, Nantasanti S, Mokry M, Huang K, Machiraju R, Fernandez S, Rosol TJ, Coppola V, Pohar KS, Pipas JM, Schmidt CR, de Bruin A, Leone G.

J Clin Invest. 2016 Aug 1;126(8):2955-69. doi: 10.1172/JCI85506. Epub 2016 Jul 25.

12.

Do amount of variant differentiation and mitotic rate in bladder cancer change with neoadjuvant chemotherapy?

Shen HM, D'Souza AM, Green IF, Pohar KS, Mortazavi A, Zynger DL.

Hum Pathol. 2015 Sep;46(9):1367-75. doi: 10.1016/j.humpath.2015.05.020. Epub 2015 Jun 4.

PMID:
26232112
13.

Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA.

Daneshmand S, Schuckman AK, Bochner BH, Cookson MS, Downs TM, Gomella LG, Grossman HB, Kamat AM, Konety BR, Lee CT, Pohar KS, Pruthi RS, Resnick MJ, Smith ND, Witjes JA, Schoenberg MP, Steinberg GD.

Nat Rev Urol. 2014 Oct;11(10):589-96. doi: 10.1038/nrurol.2014.245. Epub 2014 Sep 23. Review.

PMID:
25245244
14.

Improving bladder cancer imaging using 3-T functional dynamic contrast-enhanced magnetic resonance imaging.

Nguyen HT, Pohar KS, Jia G, Shah ZK, Mortazavi A, Zynger DL, Wei L, Clark D, Yang X, Knopp MV.

Invest Radiol. 2014 Jun;49(6):390-5. doi: 10.1097/RLI.0000000000000022.

15.

Challenges in the pathological reporting of urothelial carcinoma involving prostatic transurethral resection specimens within a single institution.

Perrino CM, Fichtenbaum EJ, Pohar KS, Zynger DL.

Pathology. 2013 Dec;45(7):664-9. doi: 10.1097/PAT.0000000000000009.

PMID:
24247624
16.

Clinicopathologic characteristics and overall survival in patients with bladder cancer involving the gastrointestinal tract.

D'Souza AM, Phillips GS, Pohar KS, Zynger DL.

Virchows Arch. 2013 Dec;463(6):811-8. doi: 10.1007/s00428-013-1479-0. Epub 2013 Oct 4.

PMID:
24092260
17.

The anatomic extent and completeness of pelvic lymphadenectomy is what matters.

Pohar KS.

Curr Opin Urol. 2013 Sep;23(5):444-8. doi: 10.1097/MOU.0b013e328363f5f8. Review.

PMID:
23851384
18.

Penile cancer: Clinical Practice Guidelines in Oncology.

Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2013 May 1;11(5):594-615.

19.

Bladder cancer.

Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M; National Comprehensive Cancer Network (NCCN).

J Natl Compr Canc Netw. 2013 Apr 1;11(4):446-75.

PMID:
23584347
20.

Retrospective analysis of survival in muscle-invasive bladder cancer: impact of pT classification, node status, lymphovascular invasion, and neoadjuvant chemotherapy.

D'Souza AM, Pohar KS, Arif T, Geyer S, Zynger DL.

Virchows Arch. 2012 Oct;461(4):467-74. doi: 10.1007/s00428-012-1249-4. Epub 2012 Aug 23.

PMID:
22915241
21.

Urinary bladder chondroma.

Perrino CM, Pohar KS, Zynger DL.

Virchows Arch. 2012 Apr;460(4):437-8. doi: 10.1007/s00428-012-1218-y. Epub 2012 Mar 7. No abstract available.

PMID:
22395484
22.

Quality of lymphadenectomy is equivalent with robotic and open cystectomy using an extended template.

Abaza R, Dangle PP, Gong MC, Bahnson RR, Pohar KS.

J Urol. 2012 Apr;187(4):1200-4. doi: 10.1016/j.juro.2011.11.092. Epub 2012 Feb 15.

PMID:
22341295
23.

Prostate-specific antigen response after definitive radiotherapy for Skene's gland adenocarcinoma resembling prostate adenocarcinoma.

Korytko TP, Lowe GJ, Jimenez RE, Pohar KS, Martin DD.

Urol Oncol. 2012 Sep;30(5):602-6. doi: 10.1016/j.urolonc.2010.06.015. Epub 2010 Sep 25.

PMID:
20870432
24.

How do commonly performed lymphadenectomy templates influence bladder cancer nodal stage?

Dangle PP, Gong MC, Bahnson RR, Pohar KS.

J Urol. 2010 Feb;183(2):499-503. doi: 10.1016/j.juro.2009.09.080. Epub 2009 Dec 14.

PMID:
20006856
25.

Management of the residual post-chemotherapy retroperitoneal mass in germ cell tumors.

Lavery HJ, Bahnson RR, Sharp DS, Pohar KS.

Ther Adv Urol. 2009 Oct;1(4):199-207. doi: 10.1177/1756287209350315.

26.

How close are we to establishing standards of lymphadenectomy for invasive bladder cancer?

Dangle PP, Bahnson RR, Pohar KS.

Ther Adv Urol. 2009 Aug;1(3):167-74. doi: 10.1177/1756287209346832.

27.

Ras-MAPK pathway as a therapeutic target in cancer--emphasis on bladder cancer.

Dangle PP, Zaharieva B, Jia H, Pohar KS.

Recent Pat Anticancer Drug Discov. 2009 Jun;4(2):125-36. Review.

PMID:
19519535
28.

Bladder cancer.

Montie JE, Clark PE, Eisenberger MA, El-Galley R, Greenberg RE, Herr HW, Hudes GR, Kuban DA, Kuzel TM, Lange PH, Lele SM, Michalski J, Patterson A, Pohar KS, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2009 Jan;7(1):8-39. No abstract available.

PMID:
19176203
29.

Inflammatory myofibroblastic tumor of epididymis: a case report and review of literature.

Dangle PP, Wang WP, Pohar KS.

World J Surg Oncol. 2008 Nov 11;6:119. doi: 10.1186/1477-7819-6-119. Review.

30.
31.

Preoperative hydronephrosis as an indicator of survival after radical cystectomy.

Chapman DM, Pohar KS, Gong MC, Bahnson RR.

Urol Oncol. 2009 Sep-Oct;27(5):491-5. doi: 10.1016/j.urolonc.2008.06.001. Epub 2008 Jul 25.

PMID:
18657452
32.

Information seeking and satisfaction with physician-patient communication among prostate cancer survivors.

Cegala DJ, Bahnson RR, Clinton SK, David P, Gong MC, Monk JP 3rd, Nag S, Pohar KS.

Health Commun. 2008;23(1):62-9. doi: 10.1080/10410230701806982.

PMID:
18443993
33.

Testicular cancer. Clinical practice guidelines in oncology.

Motzer RJ, Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Jonasch E, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pohar KS, Redman BG, Robertson CN, Samlowski WE, Sheinfeld J; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2006 Nov;4(10):1038-58. No abstract available.

PMID:
17112452
34.

Kidney cancer. Clinical practice guidelines.

Motzer RJ, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pili R, Pohar KS, Redman BG, Richey S, Robertson CN, Samlowski WE, Sheinfeld J, Urban DA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2005 Jan;3(1):84-93. No abstract available.

PMID:
19813325
35.

Results of retroperitoneal lymph node dissection for clinical stage I and II pure embryonal carcinoma of the testis.

Pohar KS, Rabbani F, Bosl GJ, Motzer RJ, Bajorin D, Sheinfeld J.

J Urol. 2003 Oct;170(4 Pt 1):1155-8.

PMID:
14501714
36.

Tomatoes, lycopene and prostate cancer: a clinician's guide for counseling those at risk for prostate cancer.

Pohar KS, Gong MC, Bahnson R, Miller EC, Clinton SK.

World J Urol. 2003 May;21(1):9-14. Epub 2003 Mar 22. Review.

PMID:
12756488
37.

Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.

Lu ML, Wikman F, Orntoft TF, Charytonowicz E, Rabbani F, Zhang Z, Dalbagni G, Pohar KS, Yu G, Cordon-Cardo C.

Clin Cancer Res. 2002 Jan;8(1):171-9.

Supplemental Content

Loading ...
Support Center